Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

The Sensex fell 721 points and the Nifty 50 dropped 225 points amid foreign fund withdrawals. Analysts predict upcoming earnings reports will influence market trends. Cipla, Bajaj Finserv, and BSE are ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The ...

Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results ...

Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in ...

Cipla reported a 10% increase in consolidated profit after tax, reaching ₹1,298 crore for Q1 FY26, driven by strong sales in ...

Cipla posted a 10.3% rise in Q1 profit with stable EBITDA margins and strong gross margin expansion helping offset pressure ...

Cipla Q1 FY26 Results Preview, Pharma Stock Price vs Nifty 50: Cipla shares are trading with cautious gains with investors ...

Ciplas Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) stood at Rs 1,778 crore, reflecting a 4% YoY growth. However, the EBITDA margin saw a marginal decline of 7 basis points, ...